This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	AT rich interactive domain 1A (ARID1A); ARID1B	Cell culture studies suggest inhibiting ARID1A or ARID1B could sensitize tumors to radiotherapy and chemotherapy. In cultured cells, siRNA knockdown of <i>ARID1A</i> , <i>ARID1B</i> and other SWI/SNF complex genes decreased accumulation of repair proteins on DNA in response to radiation and increased cisplatin-induced cell death compared with control siRNA. Next steps could include determining whether tumors with mutations in <i>ARID1A</i> or <i>ARID1B</i> are more sensitive to DNA-damaging therapies in animal models.	Patent and licensing status unavailable	Watanabe, R. <i>et al. Cancer Res.</i> ; published online May 1, 2014; doi:10.1158/0008-5472.CAN-13-3608 Contact: Akira Yasui, Tohoku University, Sendai, Japan e-mail: ayasui@idac.tohoku.ac.jp
<i>SciBX</i> 7(23); doi:10.1038/scibx.2014.670 Published online June 12, 2014				